Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of BCX9930 monotherapy in PNH (open-label extension)
2021-006776-17Phase 2Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vimircopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Long-term safety of BCX9930. Started Nov 2022; status: completed.
02
Drugs
vimircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2021-006776-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006776-17.